Innate Pharma (IPHA) Cash from Financing Activities (2019 - 2024)
Historic Cash from Financing Activities for Innate Pharma (IPHA) over the last 6 years, with Q4 2024 value amounting to -$6.4 million.
- Innate Pharma's Cash from Financing Activities fell 20350.91% to -$6.4 million in Q4 2024 from the same period last year, while for Dec 2024 it was -$9.9 million, marking a year-over-year decrease of 5550.17%. This contributed to the annual value of -$6.4 million for FY2024, which is 20350.91% down from last year.
- According to the latest figures from Q4 2024, Innate Pharma's Cash from Financing Activities is -$6.4 million, which was down 20350.91% from -$2.1 million recorded in Q4 2023.
- In the past 5 years, Innate Pharma's Cash from Financing Activities ranged from a high of -$1.0 million in Q2 2022 and a low of -$6.4 million during Q4 2024
- For the 5-year period, Innate Pharma's Cash from Financing Activities averaged around -$2.1 million, with its median value being -$1.4 million (2021).
- Its Cash from Financing Activities has fluctuated over the past 5 years, first soared by 3061.85% in 2022, then crashed by 20350.91% in 2024.
- Innate Pharma's Cash from Financing Activities (Quarter) stood at -$1.4 million in 2020, then fell by 5.21% to -$1.5 million in 2021, then fell by 26.32% to -$1.9 million in 2022, then decreased by 13.42% to -$2.1 million in 2023, then tumbled by 203.51% to -$6.4 million in 2024.
- Its Cash from Financing Activities was -$6.4 million in Q4 2024, compared to -$2.1 million in Q4 2023 and -$1.4 million in Q2 2023.